

Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function

Pulmonary function measures reflect respiratory health and are used in the diagnosis of chronic obstructive pulmonary disease. We tested genome-wide association with forced expiratory volume in 1 second and the ratio of forced expiratory volume in 1 second to forced vital capacity in 48,201 individuals of European ancestry with follow up of the top associations in up to an additional 46,411 individuals. We identified new regions showing association (combined $P < 5 \times 10^{-8}$) with pulmonary function in or near *MFAP2*, *TGFB2*, *HDAC4*, *RARB*, *MECOM* (also known as *EVII*), *SPATA9*, *ARMC2*, *NCR3*, *ZKSCAN3*, *CDC123*, *C10orf11*, *LRP1*, *CCDC38*, *MMP15*, *CFDP1* and *KCNE2*. Identification of these 16 new loci may provide insight into the molecular mechanisms regulating pulmonary function and into molecular targets for future therapy to alleviate reduced lung function.

Pulmonary function, reliably measurable by spirometry, is a heritable trait reflecting the physiological state of the airways and lungs¹. Pulmonary function measures are important predictors of population morbidity and mortality^{2–4} and are used in the diagnosis of chronic obstructive pulmonary disease (COPD), which ranks among the leading causes of death in developed and developing countries^{5,6}. A reduced ratio of forced expiratory volume in 1 second (FEV_1) to forced vital capacity (FVC) is used to define airway obstruction, and a reduced FEV_1 is used to grade the severity of airway obstruction⁷.

Recently, two large genome-wide association studies (GWAS), each comprising discovery sets of more than 20,000 individuals of European ancestry, identified new loci for lung function^{8,9}. Recognizing the need for larger data sets to increase the power to detect loci of individually modest effect size, we conducted a meta-analysis of 23 lung function GWAS comprising a total of 48,201 individuals of European ancestry (stage 1) and followed up potentially new loci in 17 further studies comprising up to 46,411 individuals (stage 2). We identified 16 additional new loci for lung function and provided evidence corroborating the association of loci previously associated with lung function^{8–11}. Our findings implicate a number of different mechanisms underlying regulation of lung function and highlight loci shared with complex traits and diseases, including height, lung cancer and myocardial infarction.

RESULTS

Genome-wide analysis (stage 1)

We undertook meta-analyses for cross-sectional lung function measures for approximately 2.5 million genotyped or imputed SNPs across 23 studies with a combined sample size of 48,201 adult individuals of European ancestry. Characteristics of the cohort participants and the genotyping are shown in **Supplementary Table 1a** and **b**. We adjusted FEV_1 and FEV_1/FVC measures for ancestry principal components, age, age², sex and height as covariates. Our association testing of the inverse-normal-transformed residuals for FEV_1 and FEV_1/FVC assumed an additive genetic model and was stratified

by ever-smoking versus never-smoking status. We performed the meta-analyses of the smoking strata within each study and of the study-specific results using inverse-variance weighting (and used the inverse of the standard error squared as the weight). We applied genomic control twice at the study level (to each smoking stratum separately and to the study-level pooled estimates) and also at the meta-analysis level to avoid inflation of the test statistics caused by cryptic population structure or relatedness (see **Supplementary Table 1a** for study-level estimates). Our application of genomic control at the three stages is likely to be overly conservative because it has recently been shown that in large meta-analyses, test statistics are expected to be elevated under polygenic inheritance even when there is no population structure¹². The test statistic inflation (λ_{GC}) before applying genomic control at the meta-analysis level was 1.12 for FEV_1 and 1.09 for FEV_1/FVC . Genomic inflation estimates increase with sample size, as has been shown for other traits^{13–15}; the standardized estimates to a sample of 1,000 individuals ($\lambda_{GC,1,000}$) were 1.002 for FEV_1 and 1.002 for FEV_1/FVC . Plots of the meta-analysis P values for FEV_1 and FEV_1/FVC against a uniform distribution of P values expected under the null hypothesis showed deviations which were attenuated, but which persisted, after removal of SNPs in loci reported previously, consistent with additional loci being associated with lung function (**Supplementary Fig. 1a**).


Follow-up analysis (stage 2)

Twenty-nine new loci showing evidence of association with lung function ($P < 3 \times 10^{-6}$) in stage 1 were followed up in stage 2 by using *in silico* data from seven studies and by undertaking additional genotyping in ten studies for the ten highest ranked SNPs (**Fig. 1**). Full details of the SNP selection are given in the Online Methods. We performed an inverse-variance-weighting meta-analysis across stages 1 and 2 and obtained two-sided P values for the pooled estimates. Sixteen new loci reached genome-wide significance ($P < 5 \times 10^{-8}$) and showed consistent direction of effects in both stages, comprising 12 new loci for FEV_1/FVC , 3 new loci for FEV_1 and 1 new locus reaching

A full list of author affiliations appears at the end of the paper.

Received 20 April; accepted 19 August; published online 25 September 2011; doi:10.1038/ng.941

Figure 1 Study design. We followed up in stage 2 a total of 34 SNPs showing new evidence of association ($P < 3 \times 10^{-6}$) with FEV_1 and/or FEV_1/FVC in a meta-analysis of the stage 1 studies. Studies with a combined total of 24,737 individuals undertook genotyping and association testing of the top ten SNPs. Seven studies (marked with an asterisk) with a combined total of 11,275 individuals had genome-wide association data and provided results for up to 34 SNPs. Researchers from GS: SFHS (marked with #) undertook genotyping on a 32-SNP multiplex genotyping platform and so included the 32 top ranking SNPs (including proxies and both SNPs from regions that showed association with both FEV_1 and FEV_1/FVC). This assay failed for one SNP (rs3769124), which was subsequently replaced with the thirty-third SNP (rs4762767). We excluded rs2284746 because of poor clustering. Although rs3743563 was chosen as proxy for rs12447804, which had an effective $N < 80\%$ in the stage 1 meta-analysis, researchers from BHS2 were unable to genotype rs3743563 and so undertook genotyping for rs12447804 instead. See **Table 1** for definitions of all study abbreviations.



genome-wide significance for both traits (**Fig. 2** and **Table 1**). To assess the heterogeneity across the studies included in stage 1 and 2, we performed χ^2 tests for all 16 SNPs, and none of these SNPs was statistically significant after applying a Bonferroni correction for 16 tests. The sentinel SNPs at these loci were in or near *MFAP2* (1p36.13), *TGFB2-LYPLAL1* (1q41), *HDAC4-FLJ43879* (2q37.3), *RARB* (3p24.2), *MECOM* (also known as *EVII*) (3q26.2), *SPATA9-RHOBTB3* (5q15), *ARMC2* (6q21), *NCR3-AIF1* (6p21.33), *ZKSCAN3* (6p22.1), *CDC123* (10p13), *C10orf11* (10q22.3), *LRP1* (12q13.3), *CCDC38* (12q22), *MMP15* (16q13), *CFDP1* (16q23.1) and *KCNE2-LINC00310* (also known as *C21orf82*) (21q22.11) (**Supplementary Fig. 1b,c**). The strongest signals in *AGER* (rs2070600)^{8,9} and two of the new signals (rs6903823 in *ZKSCAN3* and rs2857595, upstream of *NCR3*) lie within a ~3.8-Mb interval at 6p21.32-22.1 that is characterized by long-range linkage disequilibrium (LD). Nevertheless, the leading SNPs in these regions, which are within the major histocompatibility complex (MHC), were statistically independent (**Supplementary Note**).

Gene expression

We investigated mRNA expression of the nearest gene for each of the 16 new loci in human lung tissue and a range of human primary cells including lung, brain, airway smooth muscle cells and bronchial epithelial cells. We detected transcripts for all the selected genes in lung tissue except *CCDC38*, and we also detected transcripts for most genes in airway smooth muscle cells and in bronchial epithelial cells (**Table 2**). As we were unable to detect expression of *CCDC38* in any tissue, we also examined expression of *SNPRF*, which is the gene adjacent to *CCDC38* (**Table 2**), and found its expression in all four cell types. *TGFB2*, *MFAP2*, *EVII* and *MMP15* were expressed in one or more lung cell types but not in peripheral blood mononuclear cells, providing evidence that these genes may show tissue-specific expression.

We assessed whether SNPs in these new regions or their proxies ($r^2 > 0.6$) were associated with gene expression using a database of expression-associated SNPs in lymphoblastoid cell lines¹⁶. Four loci showed regional (*cis*) effects on expression ($P < 1 \times 10^{-7}$; **Supplementary Note**). A proxy for our sentinel SNP in *CFDP1*, rs2865531, coincided with the peak of the expression signal for *CFDP1*, and the strongest proxy for rs6903823 in *ZKSCAN3* coincided with the peak of expression for *ZSCAN12*.

Plausible pathways for lung function involving new loci

The putative function of the genes within, or closest to, the association peaks identify a range of plausible mechanisms for affecting lung function. The most statistically significant new signal for FEV_1/FVC ($P = 7.5 \times 10^{-16}$) was in the gene encoding *MFAP2*, an antigen of elastin-associated microfibrils¹⁷, although correlated SNPs in the region potentially implicate other genes that could plausibly influence lung function, such as *CROCC*, which encodes rootletin, a component of cilia¹⁸. Our second strongest new signal, also for FEV_1/FVC , was in *RARB*, the gene encoding the retinoic acid receptor β . *Rarb*-null knockout mice have premature alveolar septation¹⁹. The third most statistically significant new signal for FEV_1/FVC , and the most statistically significant new signal for FEV_1 , was in *CDC123*.




Figure 2 Manhattan plots of association results for FEV_1/FVC and FEV_1 (analysis stage 1). The Manhattan plots for FEV_1/FVC (**a**) and FEV_1 (**b**) are ordered by chromosome position. SNPs for which $-\log_{10} P > 5$ are indicated in red. Newly associated regions that reached genome-wide significance after meta-analysis of stages 1 and 2 are labeled.

Table 1 Loci associated with lung function

SNP ID	Chr.	NCBI36 position	Nearest gene	Coded allele	Measure	Stage 1				Stage 2				Joint meta-analysis of all stages	
						β (s.e.m.)	<i>P</i>	Coded allele freq.	<i>N</i>	β (s.e.m.)	<i>P</i>	Coded allele freq.	<i>N</i>	β (s.e.m.)	<i>P</i>
rs2284746	1	17,179,262	<i>MFAP2</i> (intron)	G	FEV ₁ /FVC	-0.042 (0.007)	2.47 × 10 ⁻⁹	0.516	45,944	-0.038 (0.007)	2.64 × 10⁻⁷	0.522	35,371	-0.04 (0.005)	7.50 × 10⁻¹⁶
					FEV ₁	0.008 (0.007)	2.78 × 10 ⁻¹			0.006 (0.007)	3.70 × 10 ⁻¹			0.007 (0.005)	1.48 × 10 ⁻¹
rs993925	1	216,926,691	<i>TGFB2</i> (downstream)	T	FEV ₁ /FVC	0.040 (0.007)	2.54 × 10 ⁻⁷	0.308	42,402	0.023 (0.01)	1.76 × 10 ⁻²	0.348	21,414	0.034 (0.006)	1.16 × 10⁻⁸
					FEV ₁	0.025 (0.007)	1.51 × 10 ⁻³			0.003 (0.007)	7.29 × 10 ⁻¹			0.014 (0.005)	8.71 × 10 ⁻³
rs12477314	2	239,542,085	<i>HDAC4</i> (downstream)	T	FEV ₁ /FVC	0.052 (0.008)	4.48 × 10 ⁻⁹	0.202	45,585	0.031 (0.008)	8.41 × 10⁻⁵	0.206	45,821	0.041 (0.006)	1.68 × 10⁻¹²
					FEV ₁	0.032 (0.008)	2.77 × 10 ⁻⁴			0.025 (0.007)	1.82 × 10⁻⁴			0.028 (0.005)	1.02 × 10 ⁻⁷
rs1529672	3	25,495,586	<i>RARB</i> (intron)	C	FEV ₁ /FVC	-0.060 (0.009)	7.75 × 10 ⁻¹⁰	0.829	40,624	-0.038 (0.009)	1.16 × 10⁻⁵	0.831	45,466	-0.048 (0.006)	3.97 × 10⁻¹⁴
					FEV ₁	-0.037 (0.009)	1.78 × 10 ⁻⁴			-0.011 (0.007)	9.33 × 10 ⁻²			-0.020 (0.007)	2.16 × 10 ⁻⁴
rs1344555	3	170,782,913	<i>MECOM</i> (intron)	T	FEV ₁ /FVC	-0.019 (0.008)	2.61 × 10 ⁻²	0.205	46,067	-0.017 (0.012)	1.55 × 10 ⁻¹	0.209	21,313	-0.018 (0.007)	6.65 × 10 ⁻³
					FEV ₁	-0.042 (0.008)	1.91 × 10 ⁻⁶			-0.025 (0.009)	6.44 × 10 ⁻³			-0.034 (0.006)	2.65 × 10⁻⁸
rs153916	5	95,062,456	<i>SPATA9</i> (upstream)	T	FEV ₁ /FVC	-0.033 (0.007)	2.06 × 10 ⁻⁶	0.552	47,530	-0.025 (0.009)	6.67 × 10 ⁻³	0.535	21,647	-0.031 (0.005)	2.12 × 10⁻⁸
					FEV ₁	-0.001 (0.007)	8.91 × 10 ⁻¹			0.004 (0.007)	6.22 × 10 ⁻¹			0.001 (0.005)	8.20 × 10 ⁻¹
rs6903823	6	28,430,275	<i>ZKSCAN3</i> (intron)/ <i>ZNF323</i> (intron)	G	FEV ₁ /FVC	-0.027 (0.008)	2.28 × 10 ⁻³	0.209	47,057	-0.013 (0.011)	2.34 × 10 ⁻¹	0.246	21,489	-0.021 (0.007)	1.19 × 10 ⁻³
					FEV ₁	-0.046 (0.008)	2.00 × 10 ⁻⁷			-0.029 (0.008)	4.75 × 10⁻⁴			-0.037 (0.006)	2.18 × 10⁻¹⁰
rs2857595	6	31,676,448	<i>NCR3</i> (upstream)	G	FEV ₁ /FVC	0.049 (0.009)	7.86 × 10 ⁻⁸	0.809	45,540	0.028 (0.008)	5.36 × 10⁻⁴	0.796	46,107	0.037 (0.006)	2.28 × 10⁻¹⁰
					FEV ₁	0.040 (0.009)	1.46 × 10 ⁻⁵			0.017 (0.007)	9.41 × 10 ⁻³			0.025 (0.005)	1.30 × 10 ⁻⁶
rs2798641	6	109,374,743	<i>ARMC2</i> (intron)	T	FEV ₁ /FVC	-0.047 (0.009)	2.81 × 10 ⁻⁷	0.183	46,369	-0.030 (0.012)	1.57 × 10 ⁻²	0.179	21,173	-0.041 (0.007)	8.35 × 10⁻⁹
					FEV ₁	-0.046 (0.009)	5.39 × 10 ⁻⁷			-0.009 (0.01)	3.35 × 10 ⁻¹			-0.030 (0.006)	4.69 × 10 ⁻⁶
rs7068966	10	12,317,998	<i>CDC123</i> (intron)	T	FEV ₁ /FVC	0.045 (0.007)	1.28 × 10 ⁻¹⁰	0.519	47,085	0.023 (0.006)	3.86 × 10⁻⁴	0.518	46,067	0.033 (0.005)	6.13 × 10⁻¹³
					FEV ₁	0.040 (0.007)	1.19 × 10 ⁻⁸			0.022 (0.005)	3.56 × 10⁻⁵			0.029 (0.004)	2.82 × 10⁻¹²
rs11001819	10	77,985,230	<i>C10orf11</i> (intron)	G	FEV ₁ /FVC	-0.019 (0.007)	6.50 × 10 ⁻³	0.522	45,546	-0.006 (0.006)	3.17 × 10 ⁻¹	0.506	45,932	-0.012 (0.005)	7.58 × 10 ⁻³
					FEV ₁	-0.041 (0.007)	1.42 × 10 ⁻⁸			-0.022 (0.005)	3.10 × 10⁻⁵			-0.029 (0.004)	2.98 × 10⁻¹²
rs11172113	12	55,813,550	<i>LRP1</i> (intron)	T	FEV ₁ /FVC	-0.035 (0.007)	1.36 × 10 ⁻⁶	0.607	45,387	-0.026 (0.01)	5.83 × 10 ⁻³	0.590	20,509	-0.032 (0.006)	1.24 × 10⁻⁸
					FEV ₁	-0.021 (0.007)	3.55 × 10 ⁻³			-0.003 (0.007)	6.94 × 10 ⁻¹			-0.013 (0.005)	1.19 × 10 ⁻²
rs1036429	12	94,795,559	<i>CCDC38</i> (intron)	T	FEV ₁ /FVC	0.049 (0.008)	1.24 × 10 ⁻⁸	0.200	47,814	0.028 (0.008)	3.35 × 10⁻⁴	0.214	46,311	0.038 (0.006)	2.30 × 10⁻¹¹
					FEV ₁	0.010 (0.008)	2.67 × 10 ⁻¹			0.004 (0.006)	5.38 × 10 ⁻¹			0.006 (0.005)	2.26 × 10 ⁻¹
rs12447804	16	56,632,783	<i>MMP15</i> (intron)	T	FEV ₁ /FVC	-0.053 (0.009)	7.12 × 10 ⁻⁸	0.208	35,123	-0.021 (0.01)	4.20 × 10 ⁻²	0.222	24,398	-0.038 (0.007)	3.59 × 10⁻⁸
					FEV ₁	-0.017 (0.009)	8.02 × 10 ⁻²			0.004 (0.007)	5.71 × 10 ⁻¹			-0.004 (0.006)	4.73 × 10 ⁻¹
rs2865531	16	73,947,817	<i>CFDP1</i> (intron)	T	FEV ₁ /FVC	0.039 (0.007)	2.30 × 10 ⁻⁸	0.418	47,594	0.024 (0.006)	1.94 × 10⁻⁴	0.409	46,304	0.031 (0.005)	1.77 × 10⁻¹¹
					FEV ₁	0.024 (0.007)	6.30 × 10 ⁻⁴			0.011 (0.005)	3.89 × 10 ⁻²			0.016 (0.004)	1.09 × 10 ⁻⁴
rs9978142	21	34,574,109	<i>KCNE2</i> (upstream)	T	FEV ₁ /FVC	-0.048 (0.009)	8.23 × 10 ⁻⁷	0.156	44,577	-0.031 (0.013)	1.75 × 10 ⁻²	0.149	20,944	-0.043 (0.008)	2.65 × 10⁻⁸
					FEV ₁	-0.012 (0.009)	2.47 × 10 ⁻¹			-0.015 (0.01)	1.35 × 10 ⁻¹			-0.013 (0.007)	5.57 × 10 ⁻²

Shown are FEV₁ and FEV₁/FVC results for the leading SNPs, ordered by chromosome and position for each independent locus associated ($P < 5 \times 10^{-8}$) with FEV₁ or FEV₁/FVC in a joint analysis of up to 94,612 individuals of European ancestry from the SpiroMeta-CHARGE GWAS (stage 1) and follow up (stage 2). Two-sided *P* values are given for stage 1, stage 2 and the joint meta-analysis of all stages. *P* values reaching genome-wide significance ($P < 5 \times 10^{-8}$) in the joint meta-analysis of all stages are indicated in bold. SNPs reaching independent replication in stage 2 ($P = 0.05/34 = 1.47 \times 10^{-3}$) are indicated with their stage 2 *P* value in bold. The sample sizes (*N*) shown are the effective sample sizes. The effective sample size within each study is the product of sample size and the imputation quality metric. The joint meta-analysis includes data from stage 1 and stage 2. β values reflect effect-size estimates on an inverse-normal transformed scale after adjustments for age, age², sex, height and ancestry principal components. The estimated proportion of the variance explained by each SNP can be found in **Supplementary Table 6**. Chr., chromosome; freq., frequency.

This was the only new region to show genome-wide association with both traits. *CDC123* encodes a homolog of a yeast cell-division-cycle protein that plays a critical role in modulating eukaryotic initiation factor 2 in times of cell stress²⁰. The fourth signal for FEV₁/FVC is downstream of *HDAC4*, which encodes a histone deacetylase; reductions in the expression of other histone deacetylases (specifically HDAC2, HDAC5 and HDAC8) have been noted in COPD²¹. The regions we observed in the MHC are much more difficult to localize, with multiple genes being tagged by the top SNP, including non-synonymous SNPs in *ZKSCAN3*, *PGBD1*, *ZSCAN12*, *ZNF323*, *TCF19*, *LTA*, *C6orf15* and *GPANK1* (also known as *BAT4*) (**Supplementary Table 2**). At 6p21.33, we observed the strongest association with lung function for rs2857595, which is in LD ($r^2 = 0.47$) with a non-synonymous SNP in *LTA* (encoding lymphotoxin α) and with a SNP in the upstream promoter region of *TNFA* (encoding tumor necrosis factor α) ($r^2 = 0.86$), both of which are plausible candidates^{22,23}. Our top SNP in *MMP15* is in strong LD ($r^2 = 1$) with a non-synonymous SNP (rs3743563, which has an association with FEV₁/FVC at $P = 1.8 \times 10^{-7}$) within the same gene. Among the plausible mechanisms implicated by the other new signals of association with lung function reported here is TGF- β signaling; *TGFB2* expression is upregulated in bronchial epithelial cells in asthma²⁴. The putative

function of key genes (as defined by LD with the leading SNP) in each of the 16 loci, and relevant findings from animal models, are summarized in **Table 2** and are detailed in **Supplementary Table 2**.

Associations with lung function in children

Alleles representing 11 of the 16 new loci showed directionally consistent effects on lung function in 6,281 children (7–9 years of age) (**Supplementary Table 3a**), suggesting that genetic determination of lung function in adults may in part act through effects on lung development, or alternatively, that some genetic determinants of lung growth and lung function decline are shared.

Association of lung function loci with other traits

Although we stratified for ever smoking versus never smoking, we did not adjust for the amount smoked. In order to investigate the possibility that the associations at any of our 16 new regions were driven by an effect of the SNP on smoking behavior, we evaluated *in silico* data for associations with smoking amount from the Oxford-GlaxoSmithKline (Ox-GSK) consortium²⁵ for the leading SNPs in these 16 regions. None of these 16 SNPs showed statistically significant association with the number of cigarettes smoked per day (**Supplementary Table 3b**).

Table 2 Expression profiling of candidate genes in the lung and periphery

Sentinel SNP (relationship to gene)	Chr.	Gene	Putative function of encoded protein	Tissue			
				Lung	HASM	HBEC	PBMC
rs993925 (intron)	1	<i>TGFB2</i>	Cytokine with roles in pro-fibrotic cytokine modulating epithelial repair mechanisms and extracellular matrix homeostasis including collagen deposition ⁴⁰ .	+	+	-	-
rs2284746 (intron)	1	<i>MFAP2</i>	Major antigen of elastin-associated microfibrils ¹⁷ and a candidate for involvement in the etiology of inherited connective tissue diseases.	+	+	+	-
rs12477314 (downstream)	2	<i>HDAC4</i>	Deacetylase of histone surrounding DNA thus influencing transcription factor access to the DNA and possibly repressing gene transcription.	+	+	+	+
rs1344555 (intron)	3	<i>EVI1</i>	Zinc finger transcription factor, encoded as part of <i>MECOM</i> (<i>MDS1-EVI1</i> complex locus).	+	+	+	-
rs1529672 (intron)	3	<i>RARB</i>	Nuclear retinoic acid receptor responsive to retinoic acid, a vitamin A derivative and which also controls cell proliferation and differentiation.	+	+	+	+
rs153916 (intron)	5	<i>SPATA9</i>	Initially identified as a mediator of spermatogenesis, other family members may have a role in pancreatic development and β -cell proliferation ⁴¹ .	+	+	+	+
rs2798641 (intron)	6	<i>ARMC2</i>	Function unknown, although other family members have been identified as having roles in cell signaling, protein degradation and cytoskeleton functions ⁴² .	+	+	+	+
rs2857595 (upstream)	6	<i>NCR3</i>	Required for efficient cytotoxicity responses by natural killer cells against normal cells and tumors ⁴³ .	+	-	-	+
rs6903823 (intron)	6	<i>ZKSCAN3</i>	Transcription factor involved in cell growth, cell cycle and signal transduction.	+	+	+	+
rs7068966 (intron)	10	<i>CDC123</i>	Homolog in yeast shown to be a critical control protein modulating eukaryotic initiation factor 2 in times of cell stress.	+	+	+	+
rs11001819 (intron)	10	<i>C10orf11</i>	Function unknown.	+	+	+	+
rs11172113 (intron)	12	<i>LRP1</i>	Potentially diverse roles including cell signaling and migration ⁴⁴ .	+	+	+	+
rs1036429 (intron)	12	<i>CCDC38</i>	Function unknown, although other family members involved in a diverse array of functions skeletal and motor function ⁴⁵ .	-	-	-	-
rs1036429 ($r^2 = 0.96$ with rs4762633 in <i>SNRPF</i>)	12	<i>SNRPF</i>	Small nuclear ribonucleoprotein F.	+	+	+	+
rs12447804 (intron)	16	<i>MMP15</i>	Member of a large protease family with diverse functional roles via protease activity and specificity including tissue remodeling, wound healing, angiogenesis and tumor invasion.	+	+	+	-
rs2865531 (intron)	16	<i>CFDP1</i>	Craniofacial development protein 1.	+	+	+	+
rs9978142 (upstream)	21	<i>KCNE2</i>	KCNQ1-KCNE2 K+ channels may modulate transepithelial anion secretion in Calu3 airway epithelial cells ⁴⁶ .	+	-	-	+
Reference gene	12	<i>GAPDH</i>		+	+	+	+

+ indicates the gene is expressed in the cell type used, and - indicates that we did not detect the gene expression at the mRNA level following 40 cycles of PCR. PCR profiling of gene transcripts in the human lung showed expression of all candidates except *CCDC38*, for which two sets of primers were designed and tested under different optimization conditions. None of these assays detected expression of *CCDC38* in the cell types analyzed. We instead assayed *SNRPF*, which neighbors *CCDC38* and harbors SNPs in strong LD with *CCDC38*'s sentinel SNP. All PCR products were sequence verified. We used *GAPDH* (encoding glyceraldehyde-3-phosphate dehydrogenase) as a positive control for the complementary DNA, and this gene was expressed in all tissues. Chr., chromosome; HASM, human airway smooth muscle; HBEC, human bronchial epithelial cells; PBMC, peripheral blood mononuclear cells.

In addition, in our stage 1 and 2 datasets combined, we assessed whether the estimated effect sizes of the variants on lung function phenotypes differed substantially between ever smokers and never smokers (**Supplementary Table 4**) across the 16 loci. For the most strongly associated trait at each locus, we tested the SNP interaction with ever smoking versus never smoking. None of the 16 new loci showed a significant interaction (Bonferroni-corrected threshold for 16 independent SNPs $P = 0.003125$). These analyses suggest that the genetic effects we have identified underlie lung function variability irrespective of smoking exposure.

We adjusted our lung function associations for height, but there are some overlaps between loci associated with height and those associated with lung function. Therefore, we evaluated *in silico* data for height associations of our new regions in the GIANT consortium¹⁴ dataset. The G allele of rs2284746 (in an intron of *MFAP2*), which was associated with decreased FEV₁/FVC, was associated with increased height (**Supplementary Table 3c**).

Given reported associations between lung cancer and either COPD or lung function decline, we also assessed *in silico* data for sentinel or proxy SNPs in these 16 regions for associations with lung cancer in the International Lung Cancer Consortium (ILCCO) GWAS meta-analysis²⁶. Alleles associated with reduced lung function were associated with risk of lung cancer at the strongest available proxy SNP for rs2857595 (upstream of *NCR3*) at 6p21.33 (rs3099844, $r^2 = 0.67$) and for the strongest proxy SNP for rs6903823 (a SNP in an intron of *ZKSCAN3* and *ZNF323*) at 6p22.1 (rs209181, $r^2 = 0.69$) (lung cancer associations at $P = 2.2 \times 10^{-7}$ and $P = 3.4 \times 10^{-5}$, respectively; **Supplementary Table 3d**). We saw no significant associations with lung cancer at the other new loci (proxy SNPs were available for 15 of the 16 loci, Bonferroni-corrected $P < 0.0033$).

In addition to the effects on height, smoking and lung cancer described above, we examined the literature for evidence of associations with other traits for each of the 16 new loci (detailed in **Supplementary Table 2**). Genome-wide significant associations ($P < 5 \times 10^{-8}$) have been reported in *KCNE2* with myocardial infarction²⁷ and at 6p21.33 near *NCR3-AIF1* with neonatal lupus²⁸ and systemic lupus erythematosus²⁹. Other significant complex disease associations have also been noted in the regions of *CDC123* (type 2 diabetes³⁰), *CFDP1* (type 1 diabetes³¹) and *MECOM* (blood pressure^{32,33}), but with weaker LD ($r^2 < 0.3$) being seen between the reported SNP and the sentinel SNP for lung function in the region (**Supplementary Table 2**).

Proportion of variance explained by loci discovered to date

Associations in ten loci previously reported for lung function^{8,9} reached genome-wide significance ($P < 5 \times 10^{-8}$) in our stage 1 data, namely loci in or near *TNSI*, *FAM13A*, *GSTCD-NPNT*, *HHIP*, *HTR4*, *ADAM19*, *AGER*, *GPR126*, *PTCH1* and *TSHD4* (**Supplementary Table 5a**). Thus, a total of 26 regions showed genome-wide significant association with lung function in our study. In aggregate, variants at these 26 regions explain approximately 3.2% of the additive polygenic variance for FEV₁/FVC and 1.5% of the variance for FEV₁ (**Supplementary Note**). Following the approach previously described³⁴, we estimated that there are a total of 102 (95% confidence interval 57–155) independent variants with similar effect sizes to the 26 variants we report here. In combination, these 102 variants, comprising 26 discovered variants and 76 putative undiscovered variants, collectively explain around 7.5% of the additive polygenic variance for FEV₁/FVC and 3.4% of the variance for FEV₁ (Online Methods, **Supplementary Table 6** and **Supplementary Note**).

DISCUSSION

In meta-analysis of 23 studies comprising 48,201 individuals of European ancestry and follow up in 17 studies comprising up to 46,411 individuals, we report genome-wide significant associations with an additional 12 regions for FEV₁/FVC, an additional 3 regions for FEV₁ and 1 additional region associated with both FEV₁ and FEV₁/FVC. We also confirmed genome-wide association with ten regions previously associated with lung function, bringing to 26 the total number of loci associated with lung function from analyses of these datasets. Most of the new loci are in regions not previously suspected to have been involved in lung development, the control of pulmonary function or the risk of developing COPD. Elucidating the mechanisms through which these regions influence lung function should lead to a more complete understanding of lung function regulation and the pathogenesis of COPD. Four of the new loci (*MFAP2*, *ZKSCAN3*, near *NCR3* and near *KCNE2*) that we showed to be associated with lung function are also associated with other complex traits and diseases (with $P < 5 \times 10^{-8}$ for the other trait at a SNP having $r^2 > 0.3$ with the top lung function SNP in the region). Understanding the intermediates underlying these pleiotropic effects could also lead to crucial insights into the pathophysiology of lung disease. One potential explanation is that these loci underlie control of the mechanisms regulating the development and resolution of inflammation and subsequent tissue remodeling in a range of tissues.

The effect sizes of the variants in the 26 loci associated with lung function collectively explain a modest proportion of the additive genetic variance in FEV₁/FVC and in FEV₁, even after accounting for putative undetected variants with a similar distribution of effect sizes³⁴. Our findings are consistent with those from other common complex traits, where it is thought that many as yet unidentified common and rare sequence variants, and potentially structural variants, could explain the remaining heritability³⁵. That our study more than doubled the number of loci known to be associated with lung function underlines the utility of large sample sizes to achieve the power to detect common variants associated with complex traits. Nevertheless, it is likely that additional variants with similar effect sizes remain undiscovered¹⁴. In addition, our study was not designed to detect rare variants or structural variants associated with lung function. Identification of rare variants associated with lung function could be helpful in narrowing the scope of ongoing functional work to those genes most likely to be causally related to the association signals we detected.

Our study focused on cross-sectional measures of lung function. Adult lung function at a particular time point is influenced by the peak lung function achieved by 25–35 years of age as well as the rate of decline of lung function after that peak³⁶. The 26 loci now confirmed to be associated with lung function could affect either pre- or post-natal lung development and growth or decline in lung function during adulthood, or both. We showed consistent directions of estimated effects on lung function between adults and children 7–9 years of age for SNPs at 11 of the 16 new loci and 8 of the 10 previously reported loci (**Supplementary Table 3a**). The results we show for lung function in children provide some indication that these loci affect lung function development, although studies in larger populations of children would provide greater clarity for SNPs in the new loci. Further investigations will be required in large populations with longitudinal data to delineate the influence of these variants on the rates of development of, and decline in, lung function and on the risk of developing COPD.

Of the sentinel SNPs at the 16 new loci associated with lung function, only rs2284746 (*MFAP2*) was associated with height in the GIANT consortium¹⁴ dataset. The G allele of rs2284746 was associated with both increased height and reduced lung function. A similar relationship

between lung function and height was previously reported for the G allele of rs3817928 in *GPR126* (refs. 8,14), which is associated with decreased height but with increased FEV₁/FVC. A further 3 of the 180 loci found to be associated with height¹⁴ showed association (for the 180 loci, we used a Bonferroni-corrected threshold of $P = 2.8 \times 10^{-4}$) with either FEV₁ (*CLIC4* and *BMP6*) or FEV₁/FVC (*PIP4K2B*) (**Supplementary Table 3e**). In each case, the allele associated with an increase in height was associated with a decrease in lung function. This is not the case for the association of rs1032296 near *HHIP*, which has shown consistent directions of effects on lung function and height^{11,14}. However, the strongest SNP associated with height in the *HHIP* region lies within an intron of *HHIP* but shows no association with FEV₁ or FEV₁/FVC. Furthermore, although height is an important predictor of FEV₁, this is not true for its ratio to FVC³⁷. These observations argue against the associations with lung function at these loci being simply caused by incomplete adjustment for height.

We stratified by ever- and never-smoker status in our analyses, and in our investigation of amount smoked in the Ox-GSK consortium²⁵, none of the sentinel SNPs in the 16 new regions showed association with the number of cigarettes smoked per day. Additionally, none of these regions was associated with ever smoking in the Ox-GSK consortium data (**Supplementary Table 3b**). Thus, the SNP associations with lung function we observed are unlikely to have arisen simply as a consequence of inadequate adjustment for smoking.

We did not observe any interactions with ever smoking for any of the sentinel SNPs in the 16 new regions that exceeded a Bonferroni-corrected significance level (for 16 SNPs). Thus, the effects on lung function of the newly associated variants we identified are apparent in both ever smokers and in never smokers, and the effects of smoking and of these genetic variants may be independent and additive.

In other common complex diseases, follow-up studies that incorporate common genetic risk variants into models to predict disease have not been shown to add substantially to existing risk models, particularly when such models already include family history^{38,39}. The same may also prove to be true for the 26 genetic variants described in this paper, as the effect size of any individual variant is small, but further work is required in this area. The major utility of our findings will be in the knowledge they provide about previously unknown pathways underlying lung function. Elucidating the mechanisms that these genes are involved in will lead to improved understanding of the regulation of lung function and potentially to new therapeutic targets for COPD.

URLs. R, <http://www.r-project.org/>.

METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturegenetics/>.

Note: Supplementary information is available on the Nature Genetics website.

ACKNOWLEDGMENTS

We thank the many colleagues who contributed to collection and phenotypic characterization of the clinical sampling, genotyping and analysis of the data. We especially thank those who kindly agreed to participate in the studies. Major funding for this work is from the following sources (alphabetical): Academy of Finland (project grants 104781, 120315, 129269, 1114194, Center of Excellence in Complex Disease Genetics (213506 and 129680) and SALVE); Althingi (Icelandic Parliament); Arthritis Research Campaign; Asthma UK; AstraZeneca; AXA Research Fund; Biotechnology and Biological Sciences Research Council (BBSRC) (BB/F019394/1, G20234); British Heart Foundation (PG/97012, PG/06/154/22043, FS05/125); British Lung Foundation; Canadian Institutes of Health Research (Grant ID MOP-82893); Cancer Research United Kingdom;

Chief Scientist Office, Scottish Government Health Directorate (CZD/16/6); Croatian Institute for Public Health; UK Department of Health; Dutch Kidney Foundation; Erasmus Medical Center and Erasmus University, Rotterdam; Estonian Genome Center, University of Tartu, Estonia (SF0180142s08); EU funding (GABRIEL GRANT Number: 018996, ECRHS II Coordination Number: QLK4-CT-1999-01237); European Commission (DG XII, EURO-BLCS, FP-5 QLG1-CT-2000-01643, FP-6 LSHB-CT-2006-018996 (GABRIEL), FP-6 LSHG-CT-2006-018947 (EUROSPAN), FP-6 GenomEUtwinn project QLG2-CT-2002-01254, FP7/2007-2013: HEALTH-F2-2008-201865, GEFOS, HEALTH-F2-2008-35627, TREAT-OA, HEALTH-F4-2007-201413 (ENGAGE)); Finnish Foundation for Cardiovascular Research; Flight Attendant Medical Research Institute (FAMRI); German Asthma and COPD Network (COSYCONET: BMBF grant 01GI0883); German Bundesministerium fuer Forschung und Technology (01 AK 803 A-H, 01 IG 07015 G); German Federal Ministry of Education and Research (BMBF) (03ZIK012, 01ZZ9603, 01ZZ0103 and 01ZZ0403); German National Genome Research Network (NGFN-2 and NGFN-plus); German Ministry of Cultural Affairs; GlaxoSmithKline; Gyllenberg Foundations; Healthway, Western Australia; Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany; Healthcare and Bioscience iNet (funded by the East Midlands Development Agency, partially financed by the European Regional Development Fund, delivered by Medilink East Midlands); Higher Education Funding Council for England (HEFCE); Hjartavernd (Icelandic Heart Association); Innsbruck Medical University; Institute for Anthropological Research in Zagreb; International Osteoporosis Foundation; Intramural Research Program of the NIH, National Institute on Aging and National Institute of Environmental Health Sciences; Jalmari and Rauha Ahokas Foundation; Juvenile Diabetes Research Foundation International (JDRF); Lifelong Health and Wellbeing Initiative (G0700704/84698); Medical Research Council UK (G1000861, G0501942, G0902313, G0000934, G0800582, G0500539, G0600705, PrevMetSyn/SALVE, G9901462); Medical Research Fund of the Tampere University Hospital; Ministry of Science, Education and Sport of the Republic of Croatia (108-1080315-0302); Medical Research Council Human Genetics Unit; Medisearch–The Leicester Medical Research Foundation; Munich Center of Health Sciences (MC Health) as part of LMUinnovativ; National Health and Medical Research Council of Australia (Grant ID 403981 and ID 003209); National Human Genome Research Institute (NHGRI) (U01-HG-004729, U01-HG-004402); National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centres (Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London and Cambridge University Hospitals NHS Foundation Trust in partnership with the University of Cambridge); Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) (050-060-810); Netherlands Organization for the Health Research and Development (ZonMw); Netherlands Organization of Scientific Research NOW (1750102007006, 175.010.2005.011, 911-03-012); Northern Netherlands Collaboration of Provinces (SNN); Norwegian University of Science and Technology; Novo Nordisk; Ontario Institute of Cancer Research and Canadian Cancer Society Research Institute (CCSRI 020214); Republic of Croatia Ministry of Science, Education and Sports research grants (108-1080315-0302); Research Institute for Diseases in the Elderly (RIDE) (014-93-015: RIDE2); Research Into Ageing (251); Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg–West Pomerania; Social Ministry of the Federal State of Mecklenburg–West Pomerania; Structure Enhancing Fund (FES) of the Dutch government; Swedish Heart and Lung Foundation grant 20050561; Swedish Research Council for Worklife and Social research (FAS), grants 2001-0263, 2003-0139; Swiss National Science Foundation (grants no. 4026-28099, 3347CO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 32-65896.01, 32-59302.99, 32-52720.97, 32-4253.94); The Asthma, Allergy and Inflammation Research Trust; The Great Wine Estates of the Margaret River region of Western Australia; The Netherlands' Ministry of Economic Affairs, Ministry of Education, Culture and Science and Ministry for Health, Welfare and Sports; The Royal Society; The University of Split and Zagreb Medical Schools; Tromsø University; U01 DK062418; UBS Wealth Foundation Grant BA29s8Q7-DZZ; UK Department of Health Policy Research Programme; University Hospital Oulu, Biocenter, University of Oulu, Finland (75617); University Medical Center Groningen; University of Bristol; University of Leicester HEFCE CIF award; University of Nottingham; US National Institutes of Health (NIH) (1P50 CA70907, R01 CA121197, U19 CA148127, CA55769, CA127219, R01HL071051, R01HL071205, R01HL071250, R01HL071251, R01HL071252, R01HL071258, R01HL071259, UL1RR025005, contracts HHSN268200625226C, HHSN268200782096C, R01-HL084099); US NIH National Cancer Institute (R01CA111703); US NIH National Center for Research Resources (grants M01-RR00425 and 5M01 RR00997); US NIH National Eye Institute (NEI); US NIH National Heart, Lung and Blood Institute (contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, N01-HC-95095, N01-HC-48047, N01-HC-48048, N01-HC-48049,

N01-HC-48050, N01-HC-45134, N01-HC-05187, N01-HC-45205, N01-HC-45204, N01-HC-25195, N01-HC-95159 through N01-HC-95169, RR-024156, N02-HL-6-4278, R01 HL-071022, R01 HL-077612, R01 HL-074104, R01 HL100543, HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C and HHSN268201100012C, grants HL080295, HL087652, HL105756, R01-HL-084099, R01HL087641, R01HL59367, R01HL086694, HL088133, HL075336, R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), 1K23HL094531-01); US NIH National Institute of Allergy and Infectious Diseases (NIAID); US NIH National Institute of Child Health and Human Development (NICHD); US NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (DK063491); US NIH National Institute of Environmental Health Sciences (NIEHS) (ZO1 ES49019, ES015794); US NIH National Institute of Mental Health (NIMH) (5R01MH63706:02); US NIH National Institute of Neurological Disorders and Stroke (NINDS); US NIH National Institute on Aging (NIA) (R01 AG032098, R01 AG035835, N01AG12100, N01AG62101, N01AG62103, N01AG62106, 1R01AG032098-01A1, AG-023269, AG-15928, AG-20098, AG-027058); Wellcome Trust (077016/Z/05/Z, GR069224, 068545/Z/02, 076113/B/04/Z, 079895).

AUTHOR CONTRIBUTIONS

Author contributions are listed in alphabetical order. See **Supplementary Note** for definitions of study acronyms.

Project conception, design and management. *Stage 1 GWAS, AGES:* G.E., M.G., V.G., T.B.H., L.J.L. *ARIC:* S.J.L., N.F., L.R.L., D.J.C., D.B.H., B.R.J., A.C.M., K.E.N. *B58C-T1DGC:* D.P.S. *B58C-WTCCC:* D.P.S. *BHSI:* A.L.J., A.W.M., L.J.P. *CHS:* S.A.G., S.R.H., T.L., B.M.P. *CROATIA-Korcula:* H.C., I.G., S.J., I.R., A.F.W., L.Z. *CROATIA-Vis:* H.C., C.H., O.P., I.R., A.F.W. *ECRHS:* D.L.J., E.O., I.P., M.W. *EPIC:* N.J.W. *FHS:* J.B.W., G.T.O. *FTC:* J.K., K.H.P., T. Rantanen. *Health ABC:* M.C.A., P.A.C., T.B.H., S.B.K., Y.L., B.M. *Health 2000:* M.H., M.K. *KORA F4:* J. Heinrich. *KORA S3:* C.G., H.-E.W. *NFBC1966:* P.E., A.-L.H., M.-R.J., A.P. *ORCADES:* H.C., S.H.W., J.F.W., A.F.W. *RS:* A. Hofman. *SHIP:* S.G., G.H., B.K., H.V. *TwinsUK:* T.D.S., G.Z. *Stage 2 follow up, ADONIX:* J. Brisman., A.-C.O. *BHS2:* J. Beilby. *BRHS:* R.W.M., S.G.W., P.H.W. *BWHHS:* G.D.S., S.E., D.A.L., P.H.W. *CARDIA:* A.S. *CROATIA-Split:* M.B., I.K., T.Z. *GS:* S.F.H.S.: C.M.J., S.M.K., A.D.M., D.J.P. *HCS:* C.C., J.W.H., A.A.S. *LBC1936:* I.J.D., S.E.H., J.M.S. *LifeLines:* H.M.B., D.S.P., J.M.V. *C.W. MESA-Lung:* R.G.B., J.L.H. *Nottingham smokers:* I.P.H. *NSHD:* R.H., D.K. *SAPALDIA:* N.P.-H., T. Rochat. *Look-up studies, ALSPAC:* R.G., J. Henderson. *ILCCO:* ILCCO data. *Ox-GSK:* C.F., J.M.

Phenotype collection and data management. *Stage 1 GWAS, AGES:* T.A. *ARIC:* D.J.C., N.F., L.R.L., A.C.M., K.E.N. *B58C-T1DGC:* A.R.R., D.P.S. *B58C-WTCCC:* A.R.R., D.P.S. *BHSI:* A.L.J., A.W.M., L.J.P. *CHS:* S.A.G., S.R.H., T.L., B.M.P. *CROATIA-Korcula:* I.G., S.J., O.P., I.R., L.Z. *CROATIA-Vis:* H.C., B.H., O.P., I.R., A.F.W. *ECRHS:* D.L.J., E.O., I.P., M.W. *EPIC:* N.J.W. *FHS:* J.B.W., G.T.O. *FTC:* J.K., K.H.P., T. Rantanen. *Health ABC:* P.A.C., B.M., W.T. *Health 2000:* M.H., M.K. *KORA F4:* S.K., H.S. *KORA S3:* N.P.-H. *NFBC1966:* P.E., A.-L.H., M.-R.J., A.P. *ORCADES:* H.C., S.H.W., J.F.W. *RS:* G.H., B.K., M.E., D.W.L., B.H.Ch.S. *SHIP:* S.G., B.K., H.V. *TwinsUK:* C.J.H., P.G. Hysi, M.M., T.D.S., G.Z. *Stage 2 follow up, ADONIX:* J. Brisman, A.-C.O. *BHS2:* J. Beilby, M.L.H. *BRHS:* R.W.M., S.G.W., P.H.W. *BWHHS:* G.D.S., S.E., D.A.L., P.H.W. *CARDIA:* O.D.W. *CROATIA-Split:* M.B., I.K., T.Z. *GS:* S.F.H.S.: C.M.J., A.D.M. *HCS:* C.C., K.A.J., A.A.S. *LBC1936:* I.J.D., L.M.L., J.M.S. *LifeLines:* D.S.P., J.M.V. *MESA-Lung:* R.G.B., J.L.H. *Nottingham smokers:* K.A.A.B., J.D.B., I.P.H., A. Henry, M.O., I. Sayers. *NSHD:* R.H., D.K. *SAPALDIA:* N.P.-H. *Look-up studies, ALSPAC:* R.G., J. Henderson. *ILCCO:* ILCCO. *Raine:* W.Q.A., P.G. Holt, C.E.P., P.D.S.

Genotyping. *Stage 1 GWAS, B58C-T1DGC:* W.L.M. *B58C-WTCCC:* W.L.M. *BHSI:* A.L.J., A.W.M., L.J.P. *CHS:* S.R.H., B.M.P., J.I.R. *CROATIA-Vis:* C.H., I.R., A.F.W. *ECRHS:* M.W. *EPIC:* I.B., R.J.F.L., J.H.Z. *FTC:* J.K. *Health ABC:* Y.L., K.L. *Health 2000:* S.R., I. Surakka. *KORA F4:* N.K. *KORA S3:* C.G. *NFBC1966:* P.E., A.-L.H., M.-R.J., A.P. *A.R. ORCADES:* H.C., J.F.W. *RS:* F.R., A.G.U. *SHIP:* G.H. *TwinsUK:* C.J.H., S.-Y.S. *Stage 2 follow up, ADONIX:* D.F., F.N., A.-C.O. *BHS2:* J. Beilby, G.C., J.H. *BRHS:* A.D.H., R.W.M. *BWHHS:* S.E., D.A.L. *CARDIA:* M.F., X.G. *CROATIA-Split:* V.B., T.Z. *Gedling:* J.R.B., T.M. *GS:* S.F.H.S.: C.M.J., S.M.K., D.J.P. *HCS:* J.W.H. *LBC1936:* I.J.D., S.E.H., L.M.L., J.M.S. *LifeLines:* C.W. *MESA-Lung:* S.S.R. *NSHD:* D.K., A.W. *SAPALDIA:* M.I., F.K. *Look-up studies, ALSPAC:* S.M.R., W.L.M. *ILCCO:* ILCCO. *Raine:* W.Q.A., C.E.P.

Data analysis. *Stage 1 GWAS, AGES:* G.K.G., A.V.S. *ARIC:* N.F., D.B.H., L.R.L. *B58C-T1DGC:* A.R.R., D.P.S. *B58C-WTCCC:* A.R.R., D.P.S. *BHSI:* N.M.W. *CHS:* K.D.M., J.I.R. *CROATIA-Korcula:* C.H., J.E.H., V.V. *CROATIA-Vis:* C.H., V.V. *ECRHS:* D.L.J., A.R. *EPIC:* J.H.Z. *FHS:* J.B.W. *FTC:* I. Surakka. *Health ABC:* P.A.C., Y.L., K.L., W.T. *Health 2000:* M.K., S.R., I. Surakka. *KORA S3:* E.A. *NFBC1966:*

A.R. ORCADES: C.H., V.V. RS: M.E., D.W.L. SHIP: S.G., G.H., B.K., H.V. TwinsUK: M.M., G.Z. Stage 2 follow-up studies, ADONIX: S.D., F.N. BHS2: G.C. BRHS: R.W.M. BWHHS: D.A.L. CARDIA: M.F., X.G. HCS: J.W.H., K.A.J. LBC1936: L.M.L. LifeLines: H.M.B. MESA-Lung: A.M., S.S.R. Nottingham smokers: I. Sayers, A. Henry. NSHD: D.G., R.H. SAPALDIA: I.C., M.I. Look-up studies, ALSPAC: D.M.E. ILCCO: ILCCO. Ox-GSK: J.Z.L. Raine: W.Q.A.

Analysis group: SpiroMeta consortium: I.P.H., T.J., M.S.A., M.D.T., L.V.W. CHARGE consortium: N.F., S.J.L., D.W.L., K.D.M., A.V.S., W.T., J.B.W.

Expression profiling and bioinformatics group: SpiroMeta consortium: I.P.H., M.O., I. Sayers, M.S.A., M.D.T., L.V.W. CHARGE consortium: S.A.G., D.W.L.

Writing group: SpiroMeta consortium: P.E., I.P.H., M.O., M.S.A., D.P.S., M.D.T., L.V.W. CHARGE consortium: S.J.L., D.W.L., S.A.G., G.T.O., V.G., B.H.Ch.S., W.T.

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturegenetics/>.

Published online at <http://www.nature.com/naturegenetics/>.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Wilk, J.B. *et al.* Evidence for major genes influencing pulmonary function in the NHLBI family heart study. *Genet. Epidemiol.* **19**, 81–94 (2000).
- Hole, D.J. *et al.* Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. *Br. Med. J.* **313**, 711–715, discussion 715–716 (1996).
- Strachan, D.P. Ventilatory function, height, and mortality among lifelong non-smokers. *J. Epidemiol. Community Health* **46**, 66–70 (1992).
- Young, R.P., Hopkins, R. & Eaton, T.E. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. *Eur. Respir. J.* **30**, 616–622 (2007).
- Lopez, A.D. *et al.* Chronic obstructive pulmonary disease: current burden and future projections. *Eur. Respir. J.* **27**, 397–412 (2006).
- Mathers, C.D. & Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med.* **3**, e442 (2006).
- Rabe, K.F. *et al.* Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am. J. Respir. Crit. Care Med.* **176**, 532–555 (2007).
- Hancock, D.B. *et al.* Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nat. Genet.* **42**, 45–52 (2010).
- Repapi, E. *et al.* Genome-wide association study identifies five loci associated with lung function. *Nat. Genet.* **42**, 36–44 (2010).
- Pillai, S.G. *et al.* A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. *PLoS Genet.* **5**, e1000421 (2009).
- Wilk, J.B. *et al.* A genome-wide association study of pulmonary function measures in the Framingham Heart Study. *PLoS Genet.* **5**, e1000429 (2009).
- Yang, J. *et al.* Genomic inflation factors under polygenic inheritance. *Eur. J. Hum. Genet.* **19**, 807–812 (2011).
- Elks, C.E. *et al.* Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. *Nat. Genet.* **42**, 1077–1085 (2010).
- Lango Allen, H. *et al.* Hundreds of variants clustered in genomic loci and biological pathways affect human height. *Nature* **467**, 832–838 (2010).
- Lindgren, C.M. *et al.* Genome-wide association scan meta-analysis identifies three loci influencing adiposity and fat distribution. *PLoS Genet.* **5**, e1000508 (2009).
- Dixon, A.L. *et al.* A genome-wide association study of global gene expression. *Nat. Genet.* **39**, 1202–1207 (2007).
- Gibson, M.A., Hughes, J.L., Fanning, J.C. & Cleary, E.G. The major antigen of elastin-associated microfibrils is a 31-kDa glycoprotein. *J. Biol. Chem.* **261**, 11429–11436 (1986).
- Yang, J. *et al.* Rootletin, a novel coiled-coil protein, is a structural component of the ciliary rootlet. *J. Cell Biol.* **159**, 431–440 (2002).
- Massaro, G.D. *et al.* Retinoic acid receptor- β : an endogenous inhibitor of the perinatal formation of pulmonary alveoli. *Physiol. Genomics* **4**, 51–57 (2000).
- Bieganski, P., Shilinski, K., Tschlis, P.N. & Brenner, C. Cdc123 and checkpoint forkhead associated with RING proteins control the cell cycle by controlling eIF2 γ abundance. *J. Biol. Chem.* **279**, 44656–44666 (2004).
- Ito, K. *et al.* Decreased histone deacetylase activity in chronic obstructive pulmonary disease. *N. Engl. J. Med.* **352**, 1967–1976 (2005).
- Wu, H. *et al.* Parental smoking modifies the relation between genetic variation in tumor necrosis factor- α (TNF) and childhood asthma. *Environ. Health Perspect.* **115**, 616–622 (2007).
- Ruse, C.E. *et al.* Tumour necrosis factor gene complex polymorphisms in chronic obstructive pulmonary disease. *Respir. Med.* **101**, 340–344 (2007).
- Chu, H.W. *et al.* Transforming growth factor- β 2 induces bronchial epithelial mucin expression in asthma. *Am. J. Pathol.* **165**, 1097–1106 (2004).
- Liu, J.Z. *et al.* Meta-analysis and imputation refines the association of 15q25 with smoking quantity. *Nat. Genet.* **42**, 436–440 (2010).
- Landi, M.T. *et al.* A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. *Am. J. Hum. Genet.* **85**, 679–691 (2009).
- Kathiresan, S. *et al.* Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat. Genet.* **41**, 334–341 (2009).
- Clancy, R.M. *et al.* Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. *Arthritis Rheum.* **62**, 3415–3424 (2010).
- Harley, J.B. *et al.* Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in *ITGAM*, *PXK*, *KIAA1542* and other loci. *Nat. Genet.* **40**, 204–210 (2008).
- Zeggini, E. *et al.* Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nat. Genet.* **40**, 638–645 (2008).
- Barrett, J.C. *et al.* Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. *Nat. Genet.* **41**, 703–707 (2009).
- Levy, D. *et al.* Genome-wide association study of blood pressure and hypertension. *Nat. Genet.* **41**, 677–687 (2009).
- Newton-Cheh, C. *et al.* Genome-wide association study identifies eight loci associated with blood pressure. *Nat. Genet.* **41**, 666–676 (2009).
- Park, J.H. *et al.* Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. *Nat. Genet.* **42**, 570–575 (2010).
- Yang, J. *et al.* Genome partitioning of genetic variation for complex traits using common SNPs. *Nat. Genet.* **43**, 519–525 (2011).
- Kohansal, R. *et al.* The natural history of chronic airflow obstruction revisited: an analysis of the framingham offspring cohort. *Am. J. Respir. Crit. Care Med.* **180**, 3–10 (2009).
- Hankinson, J.L., Odencrantz, J.R. & Fedan, K.B. Spirometric reference values from a sample of the general U.S. population. *Am. J. Respir. Crit. Care Med.* **159**, 179–187 (1999).
- Talmud, P.J. *et al.* Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. *Br. Med. J.* **340**, b4838 (2010).
- Wacholder, S. *et al.* Performance of common genetic variants in breast-cancer risk models. *N. Engl. J. Med.* **362**, 986–993 (2010).
- Thompson, H.G.R., Mih, J.D., Krasieva, T.B., Tromberg, B.J. & George, S.C. Epithelial-derived TGF- β 2 modulates basal and wound-healing subepithelial matrix homeostasis. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **291**, L1277–L1285 (2006).
- Maran, C., Tassone, E., Masola, V. & Onisto, M. The story of SPATA2 (spermatogenesis-associated protein 2): from Sertoli cells to pancreatic β -cells. *Curr. Genomics* **10**, 361–363 (2009).
- Tewari, R., Bailes, E., Bunting, K.A. & Coates, J.C. Armadillo-repeat protein functions: questions for little creatures. *Trends Cell Biol.* **20**, 470–481 (2010).
- Pende, D. *et al.* Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. *J. Exp. Med.* **190**, 1505–1516 (1999).
- Lillis, A.P., Mikhailenko, I. & Strickland, D.K. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. *J. Thromb. haemost.* **3**, 1884–1893 (2005).
- Burkhard, P., Stetefeld, J. & Strelkov, S.V. Coiled coils: a highly versatile protein folding motif. *Trends Cell Biol.* **11**, 82–88 (2001).
- Cowley, E.A. & Linsdell, P. Characterization of basolateral K⁺ channels underlying anion secretion in the human airway cell line Calu-3. *J. Physiol. (Lond.)* **538**, 747–757 (2002).

María Soler Artigas^{1,2,128}, Daan W Loth^{3,4,128}, Louise V Wain^{1,2,128}, Sina A Gharib^{5,6,128}, Ma'en Obeidat^{7,128}, Wenbo Tang^{8,128}, Guangju Zhai^{9,10}, Jing Hua Zhao¹¹, Albert Vernon Smith^{12,13}, Jennifer E Huffman¹⁴, Eva Albrecht¹⁵, Catherine M Jackson¹⁶, David M Evans¹⁷, Gemma Cadby^{18,19}, Myriam Fornage^{20,21}, Ani Manichaikul^{22,23}, Lorna M Lopez^{24,25}, Toby Johnson²⁶, Melinda C Aldrich^{27,28}, Thor Aspelund^{12,13}, Inês Barroso^{29,30}, Harry Campbell³¹, Patricia A Cassano⁸, David J Couper³², Gudny Eiriksdottir¹², Nora Franceschini³³, Melissa Garcia³⁴, Christian Gieger¹⁵, Gauti Kjartan Gislason¹², Ivica Grkovic³⁵, Christopher J Hammond⁹, Dana B Hancock^{36,37}, Tamara B Harris³⁴, Adaikalavan Ramasamy^{38–40}, Susan R Heckbert^{41–43}, Markku Heliövaara⁴⁴, Georg Homuth⁴⁵, Pirro G Hysi⁹, Alan L James^{46–48}, Stipan Jankovic³⁵, Bonnie R Joubert³⁶, Stefan Karrasch⁴⁹, Norman Klopp⁵⁰, Beate Koch⁵¹, Stephen B Kritchevsky⁵², Lenore J Launer³⁴, Yongmei Liu⁵³, Laura R Loehr³³, Kurt Lohman⁵⁴, Ruth J F Loos¹¹, Thomas Lumley⁵⁵, Khalid A Al Balushi⁷, Wei Q Ang⁵⁶, R Graham Barr⁵⁷, John Beilby^{58,59}, John D Blakey⁷, Mladen Boban⁶⁰, Vesna Boraska⁶⁰, Jonas Brisman⁶¹, John R Britton⁶², Guy G Brusselle⁶³, Cyrus Cooper⁶⁴, Ivan Curjuric^{65,66}, Santosh Dahgam⁶¹, Ian J Deary^{24,25}, Shah Ebrahim^{67,68}, Mark Eijgelsheim³, Clyde Francks⁶⁹, Darya Gaysina⁷⁰, Raquel Granell⁷¹, Xiangjun Gu²⁰, John L Hankinson⁷², Rebecca Hardy⁷⁰, Sarah E Harris^{24,73}, John Henderson⁷¹, Amanda Henry⁷, Aroon D Hingorani⁷⁴, Albert Hofman^{3,75}, Patrick G Holt⁷⁶, Jennie Hui^{48,59,77,78}, Michael L Hunter^{48,78}, Medea Imboden^{65,66}, Karen A Jameson⁶⁴, Shona M Kerr⁷⁹, Ivana Kolcic⁶⁰, Florian Kronenberg⁸⁰, Jason Z Liu⁸¹, Jonathan Marchini⁸¹, Tricia McKeever⁶², Andrew D Morris⁸², Anna-Carin Olin⁶¹, David J Porteous⁷⁹, Dirkje S Postma⁸³, Stephen S Rich²², Susan M Ring⁷¹, Fernando Rivadeneira^{3,75,84}, Thierry Rochat⁸⁵, Avan Aihie Sayer⁶⁴, Ian Sayers⁷, Peter D Sly⁷⁶, George Davey Smith¹⁷, Akshay Sood⁸⁶, John M Starr^{24,87}, André G Uitterlinden^{3,75,84}, Judith M Vonk⁸⁸, S Goya Wannamethee⁸⁹, Peter H Whincup⁹⁰, Cisca Wijmenga⁹¹, O Dale Williams⁹², Andrew Wong⁷⁰, Massimo Mangino⁹, Kristin D Marcianti^{6,41}, Wendy L McArdle⁷¹, Bernd Meibohm⁹³, Alanna C Morrison²¹, Kari E North³³, Ernst Omenaas⁹⁴, Lyle J Palmer^{18,19}, Kirsi H Pietiläinen^{95–97}, Isabelle Pin^{98–100}, Ozren Polašek^{60,101}, Anneli Pouta¹⁰², Bruce M Psaty^{6,41–43}, Anna-Liisa Hartikainen¹⁰³, Taina Rantanen¹⁰⁴, Samuli Ripatti^{97,105}, Jerome I Rotter¹⁰⁶, Igor Rudan^{31,35,101}, Alicja R Rudnicka⁹⁰, Holger Schulz¹⁰⁷, So-Youn Shin²⁹, Tim D Spector⁹, Ida Surakka^{97,105}, Veronique Vitart¹⁴, Henry Völzke¹⁰⁸, Nicholas J Wareham¹¹, Nicole M Warrington^{19,56}, H-Erich Wichmann^{107,109,110}, Sarah H Wild³¹, Jemma B Wilk¹¹¹, Matthias Wjst^{112,113}, Alan F Wright¹⁴, Lina Zgaga^{31,114}, Tatijana Zemunik⁶⁰, Craig E Pennell⁵⁶, Fredrik Nyberg^{61,115}, Diana Kuh⁷⁰, John W Holloway^{116,117}, H Marike Boezen⁸⁸, Debbie A Lawlor¹⁷, Richard W Morris⁸⁹, Nicole Probst-Hensch^{65,66}, The International Lung Cancer Consortium¹²⁷, GIANT consortium¹²⁷, Jaakko Kaprio^{44,96,97}, James F Wilson³¹, Caroline Hayward¹⁴, Mika Kähönen¹¹⁸, Joachim Heinrich¹⁰⁷, Arthur W Musk^{47,48,78,119}, Deborah L Jarvis^{38,120}, Sven Gläser¹²¹, Marjo-Riitta Järvelin^{39,102,120,122,123}, Bruno H Ch Stricker^{3,4,75,84,124,128}, Paul Elliott^{39,120,128}, George T O'Connor^{125,126,128}, David P Strachan^{90,128}, Stephanie J London^{36,128}, Ian P Hall^{7,128}, Vilmundur Gudnason^{12,13,128} & Martin D Tobin^{1,2,128}

¹Department of Health Sciences, University of Leicester, Leicester, UK. ²Department of Genetics, University of Leicester, Leicester, UK. ³Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands. ⁴Inspectorate of Healthcare, The Hague, The Netherlands. ⁵Center for Lung Biology, University of Washington, Seattle, Washington, USA. ⁶Department of Medicine, University of Washington, Seattle, Washington, USA. ⁷Division of Therapeutics and Molecular Medicine, Nottingham Respiratory Biomedical Research Unit, University Hospital of Nottingham, Nottingham, London, UK. ⁸Division of Nutritional Sciences, Cornell University Ithaca, New York, USA. ⁹Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. ¹⁰Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada. ¹¹Medical Research Council (MRC) Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. ¹²Icelandic Heart Association, Kopavogur, Iceland. ¹³University of Iceland, Reykjavik, Iceland. ¹⁴MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK. ¹⁵Institute of Genetic Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany. ¹⁶School of Medicine, University of St. Andrews, St. Andrews, Scotland, UK. ¹⁷MRC Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine, University of Bristol, Bristol, UK. ¹⁸Genetic Epidemiology and Biostatistics Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada. ¹⁹Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada. ²⁰Brown Foundation Institute of Molecular Medicine, University of Texas at Houston, Houston, Texas, USA. ²¹Human Genetics Center, School of Public Health, University of Texas at Houston, Houston, Texas, USA. ²²Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA. ²³Department of Public Health Sciences, Division of Biostatistics and Epidemiology, University of Virginia, Charlottesville, Virginia, USA. ²⁴Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, Edinburgh, UK. ²⁵Department of Psychology, The University of Edinburgh, Edinburgh, UK. ²⁶Clinical Pharmacology and the Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. ²⁷Department of Thoracic Surgery, Vanderbilt University, Nashville, Tennessee, USA. ²⁸Division of Epidemiology, Vanderbilt University, Nashville, Tennessee, USA. ²⁹Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge, UK. ³⁰University of Cambridge Metabolic Research Labs, Institute of Metabolic Science Addenbrooke's Hospital, Cambridge, UK. ³¹Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, UK. ³²Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA. ³³Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA. ³⁴Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA. ³⁵Croatian Centre for Global Health, The University of Split Medical School, Split, Croatia. ³⁶Epidemiology

Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA. ³⁷Behavioral Health Epidemiology Program, Research Triangle Institute International, Research Triangle Park, North Carolina, USA. ³⁸Respiratory Epidemiology and Public Health, Imperial College London, London, UK. ³⁹Department of Epidemiology and Biostatistics, Imperial College London, London, UK. ⁴⁰Department of Medical and Molecular Genetics, King's College London, Guy's Hospital, London, UK. ⁴¹Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, USA. ⁴²Department of Epidemiology, University of Washington, Seattle, Washington, USA. ⁴³Group Health Research Institute, Group Health Cooperative, Seattle, Washington, USA. ⁴⁴National Institute for Health and Welfare, Helsinki, Finland. ⁴⁵Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University of Greifswald, Greifswald, Germany. ⁴⁶Department of Pulmonary Physiology and Sleep Medicine/West Australian Sleep Disorders Research Institute, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. ⁴⁷The School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia. ⁴⁸Busselton Population Medical Research Foundation, Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. ⁴⁹Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilians-University, Munich, Germany. ⁵⁰Unit for Molecular Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany. ⁵¹Department of Internal Medicine B, University Hospital Greifswald, Greifswald, Germany. ⁵²Sticht Center on Aging, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. ⁵³Epidemiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. ⁵⁴Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. ⁵⁵Department of Statistics, University of Auckland, Auckland, New Zealand. ⁵⁶School of Women's and Infants' Health, The University of Western Australia, Perth, Western Australia, Australia. ⁵⁷Department of Medicine, Columbia University Medical Center, New York, New York, USA. ⁵⁸Department of Surgery and Pathology, University of Western Australia, Nedlands, Western Australia, Australia. ⁵⁹PathWest Laboratory Medicine of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia. ⁶⁰Faculty of Medicine, University of Split, Croatia, Split, Croatia. ⁶¹Occupational and Environmental Medicine, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ⁶²Division of Epidemiology and Public Health, School of Community Health Sciences and Nottingham Respiratory Biomedical Research Unit, University of Nottingham, Nottingham, UK. ⁶³Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. ⁶⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK. ⁶⁵Chronic Disease Epidemiology, Swiss Tropical and Public Health (TPH) Institute, Basel, Switzerland. ⁶⁶University of Basel, Switzerland. ⁶⁷Non-Communicable Diseases Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. ⁶⁸South Asia Centre for Chronic Disease, New Delhi, India. ⁶⁹Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands. ⁷⁰MRC Unit for Lifelong Health and Ageing, London, UK. ⁷¹School of Social and Community Medicine, University of Bristol, Bristol, UK. ⁷²Hankinson Consulting, Inc, Athens, Georgia, USA. ⁷³Medical Genetics Section, The University of Edinburgh, Edinburgh, UK. ⁷⁴Department of Epidemiology and Public Health, University College London, London, UK. ⁷⁵Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA), The Netherlands. ⁷⁶Telethon Institute for Child Health Research and Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia. ⁷⁷School of Pathology and Laboratory Medicine, The University of Western Australia, Nedlands, Western Australia, Australia. ⁷⁸School of Population Health, University of Western Australia, Nedlands, Western Australia, Australia. ⁷⁹Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. ⁸⁰Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria. ⁸¹Department of Statistics, University of Oxford, Oxford, UK. ⁸²Medical Research Institute, The University of Dundee, Dundee, UK. ⁸³Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ⁸⁴Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. ⁸⁵Division of Pulmonary Medicine, University Hospitals of Geneva, Geneva, Switzerland. ⁸⁶Department of Medicine, University of New Mexico, Albuquerque, New Mexico, USA. ⁸⁷Geriatric Medicine Unit, The University of Edinburgh, Edinburgh, UK. ⁸⁸Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ⁸⁹Department of Primary Care and Population Health, University College London, London, UK. ⁹⁰Division of Population Health Sciences and Education, St. George's University of London, London, UK. ⁹¹Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ⁹²Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, USA. ⁹³College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA. ⁹⁴Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway. ⁹⁵Obesity Research Unit, Department of Medicine, Division of Internal Medicine, Helsinki University Central Hospital, Helsinki, Finland. ⁹⁶Hjelt Institute, Department of Public Health, University of Helsinki, Helsinki, Finland. ⁹⁷Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland. ⁹⁸Pédiatrie, Centre Hospitalier Universitaire (CHU), Grenoble, France. ⁹⁹Inserm U823, Centre de Recherche Albert Bonniot, Grenoble, France. ¹⁰⁰Université Joseph Fourier, Grenoble, France. ¹⁰¹Gen-Info Ltd, Zagreb, Croatia. ¹⁰²Department of Children, Young People and Families, National Institute for Health and Welfare, Oulu, Finland. ¹⁰³Institute of Clinical Medicine, University of Oulu, Oulu, Finland. ¹⁰⁴Gerontology Research Centre, Department of Health Sciences, University of Jyväskylä, Jyväskylä, Finland. ¹⁰⁵Public Health Genomics Unit, Department of Chronic Disease Prevention, The National Institute for Health and Welfare, Helsinki, Finland. ¹⁰⁶Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. ¹⁰⁷Institute of Epidemiology I, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany. ¹⁰⁸Institute for Community Medicine, Study of Health In Pomerania (SHIP)/Clinical Epidemiological Research, University of Greifswald, Greifswald, Germany. ¹⁰⁹Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany. ¹¹⁰Klinikum Grosshadern, Munich, Germany. ¹¹¹Division of Aging, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ¹¹²Institute of Lung Biology and Disease, Comprehensive Pneumology Center, Helmholtz Zentrum München, Neuherberg, Germany. ¹¹³Institute for Medical Statistics and Epidemiology (IMSE), Technical University Munich, Munich, Germany. ¹¹⁴Andrija Stampar School of Public Health, Faculty of Medicine, University of Zagreb, Zagreb, Croatia. ¹¹⁵AstraZeneca Research and Development, Mölndal, Sweden. ¹¹⁶Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK. ¹¹⁷Infection, Inflammation and Immunity, Faculty of Medicine, University of Southampton, Southampton, UK. ¹¹⁸Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland. ¹¹⁹Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. ¹²⁰MRC Health Protection Agency (HPA) Centre for Environment and Health, Imperial College London, London, UK. ¹²¹University Hospital Greifswald, Department of Internal Medicine B, Greifswald, Germany. ¹²²Institute of Health Sciences, University of Oulu, Oulu, Finland. ¹²³Biocenter Oulu, University of Oulu, Oulu, Finland. ¹²⁴Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands. ¹²⁵Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts, USA. ¹²⁶The National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA. ¹²⁷A full list of members is provided in the **Supplementary Note**. ¹²⁸These authors contributed equally to this work. Correspondence should be addressed to M.D.T. (mt47@leicester.ac.uk) or S.J.L. (london2@niehs.nih.gov).

ONLINE METHODS

Study design. The study consisted of two stages. Stage 1 was a meta-analysis conducted on directly genotyped and imputed SNPs from individuals of European ancestry in 23 studies with a total of 48,201 individuals. **Supplementary Table 1a** gives the details of these studies. Thirty-four SNPs selected according to the results in stage 1 were followed up in stage 2. The ten leading SNPs were followed up in up to 46,411 individuals of European ancestry, and the remaining 24 SNPs were followed up in a subset of up to 21,674 individuals (**Fig. 1**).

Stage 1 samples. A total of 23 studies, 17 from the SpiroMeta consortium and 6 from the CHARGE consortium, formed stage 1: AGES, ARIC, B58C T1DGC, B58C WTCCC, BHS1, CHS, ECRHS, EPIC (obese cases and population-based studies), the EUROSPAN studies (CROATIA-Korcula, ORCADES and CROATIA-Vis), FHS, FTC (incorporating the FinnTwin16 and Finnish Twin Study on Aging), Health 2000, Health ABC, KORA F4, KORA S3, NFBC1966, RS-I, RS-II, SHIP and TwinsUK-I (see **Supplementary Table 1** for the definitions of all abbreviations). Measurements of spirometry for each study are described in the **Supplementary Note**. The genotyping platforms and quality-control criteria implemented by each study are described in **Supplementary Table 1b**.

Imputation. Imputation of non-genotyped SNPs was undertaken with MACH⁴⁷, IMPUTE⁴⁸ or BAMBAM⁴⁹ with pre-imputation filters and parameters as shown in **Supplementary Table 1b**. SNPs were excluded if the imputation information, assessed using r2.hat (MACH), .info (IMPUTE) or OEvvar (BAMBAM), was <0.3. In total, 2,706,349 SNPs were analyzed.

Transformation of data and genotype-phenotype association analysis. Linear regression of age, age², sex, height and ancestry principal components was undertaken on FEV₁ (milliliters) and FEV₁/FVC (percent). The residuals were transformed to ranks and then transformed to normally distributed z-scores. These transformed residuals were then used as the phenotype for association testing under an additive genetic model, separately for ever smokers and never smokers. The software used is specified in **Supplementary Table 1b**. Appropriate tests for association in related individuals were applied where necessary, as described in the **Supplementary Note**.

Meta-analysis of stage 1 data. All stage 1 study effect estimates, both for ever smokers and never smokers, were corrected using genomic control⁵⁰ and were oriented to the forward strand of the NCBI build 36 reference sequence of the human genome, consistently using the alphabetically higher allele as the coded allele. Study-specific λ estimates are shown in **Supplementary Table 1**. For each study, effect estimates and standard errors for ever smokers and never smokers were meta-analyzed using inverse-variance weighting. Genomic control was applied again to the pooled effect-size estimates for each study. Finally, effect-size estimates and standard errors were combined across studies using an inverse-variance-weighting meta-analysis, and genomic control was applied to the pooled effect-size estimates. To describe the effect of imperfect imputation on power, for each SNP we report the effective sample size (N effective), which is the sum of the study-specific products of the sample size and the imputation quality metric. Meta-analysis statistics and figures were produced using R version 2.9.2 (see URLs).

Selection of SNPs for stage 2. All regions selected for follow up in stage 2 contained a lead SNP with new evidence of association (all with $P < 3 \times 10^{-6}$) with FEV₁ and/or FEV₁/FVC, an N effective $\geq 70\%$ of the total stage 1 sample size and association signals from the surrounding SNPs that were consistent with their correlation (LD) with the leading SNP. Twenty-nine independent regions with a leading SNP meeting these criteria were assessed in stage 2. Regions were defined as independent if the leading SNP from one region was >500 kb from the leading SNP of any other region. Long-range LD was also investigated between leading SNPs of regions in or near the MHC on chromosome 6 (**Supplementary Note**). For two regions, the leading SNP had an N effective $\geq 70\%$ but <80% of the stage 1 sample size and, therefore, a proxy SNP from each region ($r^2 = 1$ and $r^2 = 0.97$) was also taken forward. For three regions, there were different leading SNPs for FEV₁ and FEV₁/FVC,

and so both leading SNPs were assessed. A total of 34 SNPs were analyzed in stage 2 and are listed in **Supplementary Table 5b**. Previously reported regions^{8–11,51,52} were not followed up. We present in **Supplementary Table 5a** association test statistics in stage 1 only for relevant SNPs from previously reported regions.

Stage 2 samples. The 34 SNPs were followed up in up to 11,275 individuals from seven studies with *in silico* data: CARDIA, CROATIA-Split, LifeLines, LBC1936, MESA-Lung, RS-III and TwinsUK-II (**Supplementary Table 1**). rs2647044 was not available from TwinsUK-II.

The 34 SNPs were ranked by P value (for association with either FEV₁ or FEV₁/FVC), and the top ten leading SNPs were selected for follow up by genotyping in up to 35,136 individuals from ADONIX, BHS2, BRHS, BWHHS, Gedling, GS: SFHS, HCS, Nottingham Smokers, NSHD and SAPALDIA (**Supplementary Table 1**). If a SNP in the top ten had an N effective <80%, only the proxy SNP was included in the top ten for follow up. For regions that showed association with both FEV₁ and FEV₁/FVC, only the leading SNP with the lowest P value for either trait was included if it was within the top ten SNPs. The study design is illustrated in **Figure 1**.

Meta-analysis of stage 2 data. All stage 2 studies provided effect estimates for ever smokers and never smokers, apart from Nottingham Smokers, as that study only included smokers. Studies with family data (BHS2 and GS: SFHS) analyzed ever smokers and never smokers together to account for the family correlation, adding the smoking status as a covariate in the model, and therefore provided smoking-adjusted effect estimates. All stage 2 study effect estimates were oriented to the forward strand of the NCBI build 36 reference sequence of the human genome, consistently using the alphabetically higher allele as the coded allele. For each study with separate results for ever smokers and never smokers, effect estimates and standard errors for ever smokers and never smokers were meta-analyzed using inverse-variance weighting. Genomic control was applied to the pooled effect sizes of those studies with *in silico* data that undertook the analysis genome wide. Effect estimates and standard errors were combined across the stage 2 studies using an inverse-variance-weighting meta-analysis.

Combined analysis of stage 1 and stage 2 samples. A meta-analysis of stage 1 and 2 results was undertaken using inverse-variance weighting. We described associations as genome-wide significant if they had $P < 5 \times 10^{-8}$.

PCR expression profiling. The mRNA expression profiles of *TGFB2*, *MFAP2*, *HDAC4*, *EVII*, *RARB*, *SPATA9*, *ARMC2*, *NCR3*, *CDC123*, *LRP1*, *CCDC38*, *SNRPF*, *MMP15*, *CFDP1*, *ZKSCAN3*, *KCNE2* and *C10orf11* were determined in human lung tissue and primary cell samples using RT-PCR, including RNA from lung (Ambion/ABI), brain, airway smooth muscle cells and human bronchial epithelial cells (Clonetics42). Primer sequences are listed in **Supplementary Table 2**. Full details are provided in the **Supplementary Note**.

Lung function associations in our data of SNPs previously associated with lung function. In order to permit comparison of findings with recent studies of relevance to the field, we present association test statistics (in stage 1 only) for relevant SNPs from previously reported regions (**Supplementary Table 5a**). We included the regions (i) reported as showing genome-wide significant association ($P < 5 \times 10^{-8}$) with lung function, (ii) reported as showing genome-wide significant association with COPD, providing that there was additional evidence of association with lung function and (iii) *DAAM2*, which reached borderline significance in the SpiroMeta consortium⁹. Within each of these regions, if multiple SNPs had been reported, we included all relevant SNPs and also the SNP that showed the strongest association in our data.

Association to other traits of lung-function-associated SNPs. Regions associated ($P < 5 \times 10^{-8}$) with lung function or COPD (and also associated with lung function) were looked up for other traits. Where multiple SNPs were reported for different traits or by different investigators, we aimed to include all relevant SNPs, except those having $r^2 > 0.9$ with another SNP in the region. We also included the SNPs that showed the strongest association in our data for each region. The following related traits were assessed: (i) lung function in

children (**Supplementary Table 3a**); (ii) smoking amount and ever smoking versus never smoking in the Ox-GSK consortium²⁵ dataset (**Supplementary Table 3b**); (iii) height in the GIANT consortium¹⁴ dataset (**Supplementary Table 3c,e**); and (iv) lung cancer in the International Lung Cancer Consortium (ILCCO) GWAS meta-analysis²⁶ (**Supplementary Table 3d**).

Estimation of the number of undiscovered variants and calculation of the proportion of variance explained. We used the approach previously proposed³⁴ to estimate the number of independent variants associated with lung function measures that have similar effect sizes to the variants already reported and to calculate the proportion of the variance explained by them. We excluded discovery data when estimating effect sizes to avoid winner's curse bias and obtained the number of undiscovered variants using the discovery power to detect the unbiased effect sizes (**Supplementary Table 6** and **Supplementary Note**).

Additional analyses. The top SNPs from our new loci and their proxies were searched for correlation with known common copy number variants and expression SNPs. Analyses to identify common pathways underlying the association

signals for lung function were undertaken using MAGENTA v2 (ref. 53) and GRAIL⁵⁴. Full methods and results are given in the **Supplementary Note**.

47. Li, Y. & Abecasis, G.R. Mach 1.0: rapid haplotype construction and missing genotype inference. *Am. J. Hum. Genet.* **79**, 2290 (2006).
48. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat. Genet.* **39**, 906–913 (2007).
49. Servin, B. & Stephens, M. Imputation-based analysis of association studies: candidate regions and quantitative traits. *PLoS Genet.* **3**, e114 (2007).
50. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997–1004 (1999).
51. Cho, M.H. *et al.* Variants in *FAM13A* are associated with chronic obstructive pulmonary disease. *Nat. Genet.* **42**, 200–202 (2010).
52. Pillai, S.G. *et al.* Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **182**, 1498–1505 (2010).
53. Segrè, A.V., Groop, L., Mootha, V.K., Daly, M.J. & Altshuler, D. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. *PLoS Genet.* **6**, e1001058 (2010).
54. Raychaudhuri, S. *et al.* Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. *PLoS Genet.* **5**, e1000534 (2009).